Improved Survival in BRAF-Mutated Melanoma With Trametinib | MedIndia

Posted on June 12, 2012 | Leave a comment

Improved Survival in BRAF-Mutated Melanoma With Trametinib | MedIndia

 Trametinib, a MEK inhibitor, promotes survival in advanced melanoma patients with mutations in serine–threonine protein kinase B-RAF (BRAF).

 
http://www.medindia.net/news/healthwatch/improved-survival-in-braf-mutated-melanoma-with-trametinib-102573-1.htm#
This entry was posted in Uncategorized. Bookmark the permalink.

Leave a comment